Y-mAbs Therapeutics, Inc. (YMAB) Unveils Promising Cancer Trial Data at ANR 2025
Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has presented the early-stage clinical data from its GD2-SADA PRIT trial at the Advances in Neuroblastoma Research (ANR) Meeting in Washington, D.C.